A Phase 2 Study of Trametinib for Patients With Pediatric Glioma or Plexiform Neurofibroma With Refractory Tumor and Activation of the MAPK/ERK Pathway.
Phase of Trial: Phase II
Latest Information Update: 23 Nov 2018
At a glance
- Drugs Trametinib (Primary)
- Indications CNS cancer; Glioma; Neurofibromatoses; Plexiform neurofibroma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 09 Aug 2018 Status changed from not yet recruiting to recruiting.
- 16 Apr 2018 Planned initiation date changed from 1 Mar 2018 to 15 May 2018.